Glucagon
Also known as: GlucaGen, Baqsimi
Key Facts: Glucagon
- Category
- Hormonal
- FDA Status
- FDA Approved
- Clinical Status
- FDA Approved - Hypoglycemia and diagnostic
- Administration
- Injection, intranasal, or auto-injector
- Typical Dose
- Limited community data available
- Frequency
- See research protocols
- Duration
- Single dose emergency use
Mechanism of Action
Glucagon binds the glucagon receptor (GCGR), a seven-transmembrane G-protein-coupled receptor concentrated in the liver. The receptor couples to Gs, which switches on adenylate cyclase and floods the cell with the second messenger cAMP, activating protein kinase A (PKA). PKA then drives two pathways at once: it ramps up glycogenolysis (breaking glycogen back down into glucose) and gluconeogenesis (making fresh glucose), in part by activating enzymes like PEPCK and glucose-6-phosphatase. The net effect is the liver dumping glucose into the bloodstream. Glucagon and insulin work as an opposing pair to keep blood sugar in a tight range.
Research Summary
Glucagon's physiology and clinical role are textbook-settled, not experimental. It is FDA-approved and widely used as the standard rescue agent for severe hypoglycemia, and newer ready-to-use formulations (a nasal powder and stable liquid auto-injectors) have made it far easier for non-medical bystanders to give in an emergency. Receptor-level studies, including GCGR knockout mouse work, confirm that glucagon signaling through GCGR/PKA controls hepatic glucose output, and chronic glucagon excess (hyperglucagonemia) is linked to worse glucose control in diabetes. That last point is exactly why glucagon-receptor biology now sits at the center of next-generation metabolic drugs: several investigational obesity and diabetes agents (such as dual and triple incretin agonists) deliberately engage GCGR to boost energy expenditure. So beyond the established rescue use, glucagon is a hot target in current metabolic drug research.
Dosing Information
Typical Dosingⓘ
Community experience
Limited community data available
See research dosing
See research protocols
Research Dosingⓘ
Scientific studies
Emergency dosing
Doses from Studies
1 mg IM/SC/IV for hypoglycemia
3 mg intranasal (Baqsimi)
Duration
Single dose emergency use
Administration
Injection, intranasal, or auto-injector
Timing & Administration
Best Time to Take
Morning
Follow specific protocol
Food Recommendation
Take on empty stomach
Why This Timing?
Metabolic peptides often work best when taken in the morning to support daytime energy expenditure.
Possible Side Effects
Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.
- ●Nausea (up to 35%)
- ●Vomiting
- ●Headache
- ●Hypertension
- ●Tachycardia
- ●Allergic reactions
- ●Rebound hypoglycemia
- ●CONTRAINDICATED with pheochromocytoma
- ●FDA approved
References
- https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/glucagon-receptor
- https://pmc.ncbi.nlm.nih.gov/articles/PMC3130710/
- https://www.tandfonline.com/doi/full/10.2217/bmm-2016-0090
- https://journals.physiology.org/doi/full/10.1152/physiol.00030.2005
Research This Peptide Further
Frequently Asked Questions
What does Glucagon do?
Glucagon is insulin's counterweight, a 29-amino-acid peptide hormone secreted by the alpha cells of the pancreas that raises blood sugar instead of lowering it. When glucose drops, glucagon tells the liver to break down stored glycogen and make new glucose, pushing blood sugar back up. Medically it is the emergency rescue treatment for severe hypoglycemia (the kind that knocks out a person with diabetes), available as injectable kits and a nasal-spray form, and it is also used in some diagnostic imaging to relax the gut.
How does Glucagon work?
Glucagon binds the glucagon receptor (GCGR), a seven-transmembrane G-protein-coupled receptor concentrated in the liver. The receptor couples to Gs, which switches on adenylate cyclase and floods the cell with the second messenger cAMP, activating protein kinase A (PKA). PKA then drives two pathways at once: it ramps up glycogenolysis (breaking glycogen back down into glucose) and gluconeogenesis (making fresh glucose), in part by activating enzymes like PEPCK and glucose-6-phosphatase. The net effect is the liver dumping glucose into the bloodstream. Glucagon and insulin work as an opposing pair to keep blood sugar in a tight range.
Is Glucagon FDA approved?
Yes, Glucagon is FDA approved. FDA Approved - Hypoglycemia and diagnostic
What are the side effects of Glucagon?
Reported side effects include: Nausea (up to 35%), Vomiting, Headache, Hypertension, Tachycardia. Individual responses vary based on dosage, duration, and personal health factors.
What is the typical dose of Glucagon?
Community-reported common dose: Limited community data available (See research protocols). Range: See research dosing. Administration: Injection, intranasal, or auto-injector. Community-reported doses. Not medical advice. Consult healthcare provider.
Related Peptides
Peptides commonly compared with Glucagon or used in similar applications.
Octreotide
FDAOctreotide is a synthetic eight-amino-acid mimic of the natural hormone somatostatin, the body's main 'off switch' for hormone secretion. It shuts down excess growth hormone, so it is a frontline FDA-approved drug for acromegaly, and it also tames the flushing and diarrhea of hormone-secreting carcinoid and other neuroendocrine tumors. This is real, approved medicine with decades of clinical data behind it, sold as Sandostatin (injectable, since 1988), Sandostatin LAR (monthly depot), and Mycapssa (oral capsule, approved 2020).
HormonalPasireotide
FDAPasireotide (brand name Signifor) is a second-generation somatostatin analog, a cyclic six-amino-acid peptide engineered to hit more receptor subtypes than octreotide or lanreotide. Its standout use is Cushing's disease, where it was the first drug FDA-approved (2012) to directly target the pituitary tumor driving cortisol excess, and it is also approved for acromegaly that resists first-line analogs. The catch is real and well known: it raises blood sugar in most patients, so it is a powerful but high-maintenance option.
HormonalInsulin
FDAInsulin is the body's main blood-sugar-lowering hormone, a 51-amino-acid protein made of two chains (a 21-residue A-chain and a 30-residue B-chain) held together by disulfide bonds. Secreted by the beta cells of the pancreas, it tells the liver, muscle, and fat to take up glucose and store energy. Discovered in 1921 and first given to a patient in January 1922, it remains one of the most consequential drugs in medicine and is the cornerstone of treatment for type 1 and many cases of type 2 diabetes.
HormonalOxytocin
FDAOxytocin is a 9-amino-acid hormone made in the hypothalamus, famous as the chemistry behind labor contractions, breastfeeding, and social bonding. As an injectable drug it is FDA-approved to induce labor and control postpartum bleeding, but the intranasal 'love hormone' versions sold for trust, anxiety, and autism are experimental and the human results are genuinely mixed. The hype runs well ahead of the evidence.
HormonalGonadorelin
FDAGonadorelin is a synthetic copy of natural GnRH (gonadotropin-releasing hormone), a 10-amino-acid peptide (pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2) that tells the pituitary to release LH and FSH. It is FDA-approved for evaluating pituitary function and has historical use in inducing ovulation. In the peptide world it is mostly used off-label to keep the testes working during testosterone replacement, and the catch is that timing matters enormously: pulse it and you stimulate, give it continuously and you shut the system down.
HormonalLeuprolide
FDALeuprolide (brand name Lupron) is a synthetic GnRH agonist, a modified peptide about 20 times more potent than natural GnRH, and it is FDA-approved for advanced prostate cancer, endometriosis, uterine fibroids, and central precocious puberty. The clever part is counterintuitive: it works by overstimulating the GnRH system so hard that the pituitary shuts down sex hormone production. It is a real, long-established prescription drug, not a research peptide, and it carries meaningful side effects from the low-hormone state it creates.
HormonalWant updates on Glucagon research?
Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.